ROS-triggered transformation of microgels to bioadhesive patch for orally administrated treatment of inflammatory bowel disease
Source abstract
Abstract
Inflammatory bowel diseases (IBD) are driven by excessive reactive oxygen species (ROS) and progressive disruption of the intestinal mucus barrier, yet sustained mucosal protection remains insufficiently addressed by current therapies. Here, we develop an orally administered, inflammation-activated microgel system (iPatch) that undergoes a ROS-triggered microgel-to-patch transformation specifically at inflamed intestinal sites. Unlike pre-formed hydrogels or enema-based formulations, this in situ transformation enables prolonged mucosal retention, adaptive barrier reconstruction, and sequential dual-drug release after oral dosing. In colitis mouse models, iPatch restores epithelial integrity, suppresses inflammation, and significantly improves clinical outcomes. This self-transforming oral patch system offers a patient-friendly and mechanistically distinct strategy for IBD treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inflammatory Bowel Disease · Hydrogels: synthesis, properties, applications · Gut microbiota and health
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies10.1053/j.gastro.2015.06.001 ↗
2. Ulcerative colitis10.1056/NEJMra1102942 ↗
3. Crohn's disease10.1016/S0140-6736(12)60026-9 ↗
4. Surgery for inflammatory bowel disease10.3748/wjg.14.2678 ↗
5. Microbiota-immune interactions in ulcerative colitis and colitis associated cancer and emerging microbiota-based therapies10.3390/ijms222111365 ↗
6. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?10.1038/s41575-022-00604-y ↗
7. Mucosal profiling of pediatric-onset colitis and IBD reveals common pathogenics and therapeutic pathways10.1016/j.cell.2019.10.027 ↗
8. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment
9. IBD disease-modifying therapies: insights from emerging therapeutics10.1016/j.molmed.2023.01.001 ↗
10. Action of reactive oxygen species on colonic mucus secretions10.1016/j.freeradbiomed.2007.05.023 ↗
11. Reactive oxygen species limit intestinal mucosa-bacteria homeostasis in vitro10.1038/s41598-021-02080-x ↗
12. Cyclized polyacrylonitrile nanoparticles: enhanced intratumoral delivery by photocatalysis and collagen denaturation10.1016/j.jcis.2025.137829 ↗
13. Epigenetic remodeling under oxidative stress: mechanisms driving tumor metastasis10.1002/mog2.70000 ↗
14. Oxidative stress and cellular senescence: roles in tumor progression and therapeutic opportunities10.1002/mog2.70007 ↗
15. Current and emerging therapeutic targets for IBD10.1038/nrgastro.2016.208 ↗
16. Oral metal-free melanin nanozymes for natural and durable targeted treatment of inflammatory bowel disease (IBD)
17. Efficient therapy of inflammatory bowel disease (IBD) with highly specific and durable targeted Ta2C modified with chondroitin sulfate (TACS)10.1002/adma.202301585 ↗
18. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis10.1038/s41563-019-0462-9 ↗
19. Gram-scale preparation of quercetin supramolecular nanoribbons for intestinal inflammatory diseases by oral administration10.1016/j.biomaterials.2023.122039 ↗
20. Stimulation-responsive mucoadhesive probiotics for inflammatory bowel disease treatment by scavenging reactive oxygen species and regulating gut microbiota10.1016/j.biomaterials.2023.122274 ↗
21. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway10.1038/s41467-018-07859-7 ↗
22. Modulation of gut barrier functions in ulcerative colitis by hyaluronic acid system
23. Hydrogel derived from decellularized porcine small intestinal submucosa as a physical shielding repaired the gut epithelial barrier of murine ulcerative colitis10.1002/adfm.202405601 ↗
24. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease10.1126/scitranslmed.aaa5657 ↗
25. Hydrogel-based artificial mucosa restores local immune and microbial homeostasis for treating ulcerative colitis10.1002/adfm.202212566 ↗
26. Biomimetic supramolecular assembly with IGF-1C delivery ameliorates inflammatory bowel disease (IBD) by restoring intestinal barrier integrity10.1002/advs.202403075 ↗
27. Gelnb molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease
28. Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease
29. Injectable zwitterionic hydrogels for biomedical applications: design strategies and emerging trends
30. Pathological features-based targeted delivery strategies in IBD therapy: a mini review10.1016/j.biopha.2022.113079 ↗
31. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease10.1016/j.biopha.2020.110486 ↗
32. An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer10.1038/s41565-025-01904-5 ↗
33. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal permeability-increasing protein10.1053/gast.1996.v110.pm8608882 ↗
34. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia10.1073/pnas.052533799 ↗
35. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease10.1016/j.nantod.2017.08.006 ↗
36. Oxalate/hydrogen peroxide chemiluminescence reaction. A 19F NMR probe of the reaction mechanism10.1002/bmc.1130040304 ↗
37. Studies on the chemiexcitation step in peroxyoxalate chemiluminescence using steroid-substituted activators10.1002/bio.694 ↗
38. Dual-ROS sensitive moieties conjugate inhibits curcumin oxidative degradation for colitis precise therapy10.1002/adhm.202303016 ↗
39. Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis10.1038/s41467-023-39013-3 ↗
40. Adhesive polyelectrolyte coating through uv-triggered polymerization on plga particles for enhanced drug delivery to inflammatory intestinal mucosa10.1186/s12951-024-03066-3 ↗
41. An olsalazine nanoneedle-embedded inulin hydrogel reshapes intestinal homeostasis in inflammatory bowel disease
42. Microalgae-based hydrogel for inflammatory bowel disease and its associated anxiety and depression10.1002/adma.202312275 ↗
43. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery10.1038/s41467-022-31171-0 ↗
44. Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease10.1016/j.biomaterials.2022.121364 ↗
45. Oral delivery of bioactive glass-loaded core-shell hydrogel microspheres for effective treatment of inflammatory bowel disease10.1002/advs.202207418 ↗
46. Adhesive polyelectrolyte coating on plga particles prolongs drug retention to vessel lesion10.1016/j.jconrel.2024.12.068 ↗
47. Paracellular permeability and tight junction regulation in gut health and disease10.1038/s41575-023-00766-3 ↗
48. TSP50 attenuates dss-induced colitis by regulating TGF-β signaling mediated maintenance of intestinal mucosal barrier integrity
49. Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease10.1016/j.molmed.2020.06.006 ↗
50. The emerging role of oxidative stress in inflammatory bowel disease10.3389/fendo.2024.1390351 ↗
51. Auphos, a “first-in class” oral agent for correcting metabolic dysfunction in IBD10.1053/j.gastro.2021.12.010 ↗
52. Mucins and their role in shaping the functions of mucus barriers10.1146/annurev-cellbio-100617-062818 ↗
53. QbD-based fabrication of transferrin-anchored nanocarriers for targeted drug delivery to macrophages and colon cells for mucosal inflammation healing10.1039/D2BM01719A ↗
54. Intestinal barrier in inflammatory bowel disease10.3748/wjg.v20.i5.1165 ↗
55. Study of conformation and thermodynamics of α-amylase interaction with ethylene in vitro10.1016/j.jphotobiol.2016.08.021 ↗
56. An off-the-shelf bioadhesive patch for sutureless repair of gastrointestinal defects10.1126/scitranslmed.abh2857 ↗
57. An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection
58. Instant tough bioadhesive with triggerable benign detachment10.1073/pnas.2006389117 ↗
59. Aminosalicylates target GPR35, partly contributing to the prevention of dss-induced colitis10.1016/j.ejphar.2023.175719 ↗
60. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis10.1002/ibd.21318 ↗
61. Association of alterations in intestinal microbiota with impaired psychological function in patients with inflammatory bowel diseases in remission10.1016/j.cgh.2019.09.022 ↗
62. Adverse effect of oxidized cholesterol exposure on colitis is mediated by modulation of gut microbiota10.1016/j.jhazmat.2023.132057 ↗
63. An engineered butyrate-derived polymer nanoplatform as a mucosa-healing enhancer potentiates the therapeutic effect of magnolol in inflammatory bowel disease10.1021/acsnano.3c05732 ↗
64. The combination of bacillus natto JLCC513 and ginseng soluble dietary Fiber attenuates ulcerative colitis by modulating the LPS/TLR4/NF-κB pathway and gut microbiota10.4014/jmb.2402.02027 ↗
65. Influencing inter-cellular junctions with nanomaterials10.1016/j.cis.2024.103372 ↗
66. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway10.1136/gutjnl-2017-313778 ↗